Perspectives on interactions between paediatricians and the pharmaceutical industry

Paediatrics and Child Health

Volumn 10, Issue 3, 2005, Pages 147-148

  Rieder, Michael J ^a,b  

^a CHILDREN S HOSPITAL OF WESTERN ONTARIO   (Canada)

^b WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PENICILLIN G; SULFONAMIDE;

ANTIBACTERIAL ACTIVITY; CLINICAL PRACTICE; CONTINUING EDUCATION; DRUG COST; DRUG INDUSTRY; EDITORIAL; MEDICAL RESEARCH; PEDIATRICIAN; RISK ASSESSMENT; TREATMENT FAILURE;

EID: 17644415416     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (3)

1. Thomas L. The Youngest Science: Notes of a Medicine-Watcher. New York: Viking Press, 1983.
2. Weinshilboum RM. The therapeutic revolution. Clin Pharmacol Ther 1987;42:481-4.
3. Coyle SL, for the American College of Physicians - American Society of Internal Medicine, Ethics and Human Rights Committee. Physician-industry relations. Part 1: Individual physicians. Ann Intern Med 2002;136:396-402.